Urticarial vasculitis in patients with chronic hepatitis C virus as an interdisciplinary problem

Abstract

Urticarial vasculitis is a skin disease characterized by recurrent urticarial lesions and histological features of leukocytoclastic vasculitis. Urticarial vasculitis is known to occur in the association with various infectious diseases, including chronic hepatitis C virus. However, the clinical features of urticarial vasculitis associated with hepatitis C virus have not been systematically characterized, which complicates the management of these patients.

This review presents an analysis of published clinical, histological and laboratory findings in patients with urticarial vasculitis in the association with chronic hepatitis C virus, which can be helpful for early diagnosis and optimization of the patient management.

We performed a Pubmed search to identify clinical cases from 1971 to 2022 using the keywords "urticarial vasculitis", "hepatitis C virus infection". According to the inclusion/exclusion criteria, 13 clinical cases of urticarial vasculitis associated with hepatitis C virus were included in the analysis.

Clinical manifestations were urticarial rashes (n=13), associated with residual hyperpigmentation in 8 patients, tenderness/burning ― in 7 patients, and a lesion duration (>24 hours) ― in five patients. Arthralgias were described in 3 patients.

On histological examination, there were fibrinoid necrosis (n=2); leukocytoclasia (n=4); erythrocyte extravasation (n=1); dermis edema (n=2); perivascular infiltrate consisting of neutrophils (n=5), eosinophils (n=4), lymphocytes (n=3), and histiocytes (n=2). Hypocomplementemia was reported in eight patients. The laboratory work revealed cryoglobulinemia (n=9) and positive rheumatoid factor (n=6), which were the characteristic findings in the association of these diseases.

The association of urticarial vasculitis and chronic hepatitis C virus is an important interdisciplinary problem that requires an interaction of dermatologists, allergists, hepatologists, rheumatologists and infectious disease doctors. Histological examination is indicated to differentiate between urticaria and urticarial vasculitis in patients with atypical urticarial lesions. Early detection of chronic hepatitis C virus is necessary for the timely administration of antiviral therapy. The urticarial vasculitis treatment should be selected taking into account their efficacy and the risk of hepatotoxicity.

Keywords

urticarial vasculitis / chronic hepatitis C virus / urticarial lesions

References

[1] Gu SL, Jorizzo JL. Urticarial vasculitis. Int J Womens Dermatol. 2021;7(3):290–297. doi: 10.1016/j.ijwd.2021.01.021

[2] Gu S.L., Jorizzo J.L. Urticarial vasculitis // Int J Womens Dermatol. 2021. Vol. 7, N 3. Р. 290–297. doi: 10.1016/j.ijwd.2021.01.021

[3] Crowson AN, Nuovo G, Ferri C, Magro CM. The dermatopathologic manifestations of hepatitis C infection: A clinical, histological, and molecular assessment of 35 cases. Hum Pathol. 2003;34(6):573–579. doi: 10.1016/s0046-8177(03)00193-x

[4] Crowson A.N., Nuovo G., Ferri C., Magro C.M. The dermatopathologic manifestations of hepatitis C infection: a clinical, histological, and molecular assessment of 35 cases // Hum Pathol. 2003. Vol. 34, N 6. Р. 573–579. doi: 10.1016/s0046-8177(03)00193-x

[5] Kolkhir P, Pereverzina N, Olisova O, Maurer M. Comorbidity of viral hepatitis and chronic spontaneous urticaria: A systematic review. Allergy. 2018;73(10):1946–1953. doi: 10.1111/all.13482

[6] Kolkhir P., Pereverzina N., Olisova O., Maurer M. Comorbidity of viral hepatitis and chronic spontaneous urticaria: A systematic review // Allergy. 2018. Vol. 73, N 10. Р. 1946–1953. doi: 10.1111/all.13482

[7] Cribier BJ, Santinelli F, Schmitt C, et al. Chronic urticaria is not significantly associated with hepatitis C or hepatitis G infection: A case-control study. Arch Dermatol. 1999;135(11):1335–1339. doi: 10.1001/archderm.135.11.1335

[8] Cribier B.J., Santinelli F., Schmitt C., et al. Chronic urticaria is not significantly associated with hepatitis C or hepatitis G infection: A case-control study // Arch Dermatol. 1999. Vol. 135, N 11. Р. 1335–1339. doi: 10.1001/archderm.135.11.1335

[9] Kanazawa K, Yaoita H, Tsuda F, Okamoto H. Hepatitis C virus infection in patients with urticaria. J Am Acad Dermatol. 1996;35(2 Pt 1):195–198. doi: 10.1016/s0190-9622(96)90322-9

[10] Kanazawa K., Yaoita H., Tsuda F., Okamoto H. Hepatitis C virus infection in patients with urticaria // J Am Acad Dermatol. 1996. Vol. 35, N 2, Pt 1. Р. 195–198. doi: 10.1016/s0190-9622(96)90322-9

[11] Pakula AS, Garden JM, Roth SI. Cryoglobulinemia and cutaneous leukocytoclastic vasculitis associated with hepatitis C virus infection. J Am Acad Dermatol. 1993;28(5 Pt 2):850–853. doi: 10.1016/0190-9622(93)70116-b

[12] Pakula A.S., Garden J.M., Roth S.I. Cryoglobulinemia and cutaneous leukocytoclastic vasculitis associated with hepatitis C virus infection // J Am Acad Dermatol. 1993. Vol. 28, N 5, Pt 2. Р. 850–853. doi: 10.1016/0190-9622(93)70116-b

[13] Johnson RJ, Willson R, Yamabe H, et al. Renal manifestations of hepatitis C virus infection. Kidney Int. 1994;46(5):1255–1263. doi: 10.1038/ki.1994.393

[14] Johnson R.J., Willson R., Yamabe H., et al. Renal manifestations of hepatitis C virus infection // Kidney Int. 1994. Vol. 46, N 5. Р. 1255–1263. doi: 10.1038/ki.1994.393

[15] Kobayashi S, Nagase M, Hidaka S, et al. Membranous nephropathy associated with hypocomplementemic urticarial vasculitis: Report of two cases and a review of the literature. Nephron. 1994;66(1):1–7. doi: 10.1159/000187758

[16] Kobayashi S., Nagase M., Hidaka S., et al. Membranous nephropathy associated with hypocomplementemic urticarial vasculitis: Report of two cases and a review of the literature // Nephron. 1994. Vol. 66, N 1. Р. 1–7. doi: 10.1159/000187758

[17] Lin RY, Caren CB, Menikoff H. Hypocomplementaemic urticarial vasculitis, interstitial lung disease and hepatitis C. Br J Dermatol. 1995;132(5):821–823. doi: 10.1111/j.1365-2133.1995.tb00734.x

[18] Lin R.Y., Caren C.B., Menikoff H. Hypocomplementaemic urticarial vasculitis, interstitial lung disease and hepatitis C // Br J Dermatol. 1995. Vol. 132, N 5. Р. 821–823. doi: 10.1111/j.1365-2133.1995.tb00734.x

[19] Kuniyuki S, Katoh H. Urticarial vasculitis with papular lesions in a patient with type C hepatitis and cryoglobulinemia. J Dermatol. 1996;23(4):279–283. doi: 10.1111/j.1346-8138.1996.tb04013.x

[20] Kuniyuki S., Katoh H. Urticarial vasculitis with papular lesions in a patient with type C hepatitis and cryoglobulinemia // J Dermatol. 1996. Vol. 23, N 4. Р. 279–283. doi: 10.1111/j.1346-8138.1996.tb04013.x

[21] Hamid S, Cruz PD, Lee WM. Urticarial vasculitis caused by hepatitis C virus infection: Response to interferon alfa therapy. J Am Acad Dermatol. 1998;39(2 Pt 1):278–280. doi: 10.1016/s0190-9622(98)70089-1

[22] Hamid S., Cruz P.D., Lee W.M. Urticarial vasculitis caused by hepatitis C virus infection: response to interferon alfa therapy // J Am Acad Dermatol. 1998. Vol. 39, N 2, Pt 1. Р. 278–280. doi: 10.1016/s0190-9622(98)70089-1

[23] Kelkar PS, Butterfield JH, Kalaaji AN. Urticarial vasculitis with asymptomatic chronic hepatitis C infection: Response to doxepin, interferon-alfa, and ribavirin. J Clin Gastroenterol. 2002;35(3):281–282. doi: 10.1097/00004836-200209000-00017

[24] Kelkar P.S., Butterfield J.H., Kalaaji A.N. Urticarial vasculitis with asymptomatic chronic hepatitis C infection: Response to doxepin, interferon-alfa, and ribavirin // J Clin Gastroenterol. 2002. Vol. 35, N 3. Р. 281–282. doi: 10.1097/00004836-200209000-00017

[25] Sanli H, Ozdemir E. Ig M class anticardiolipin antibody and anti-Ro/SS-A positivity in urticarial vasculitis associated with hepatitis C virus infection. Int J Dermatol. 2002;41(12):930–932. doi: 10.1046/j.1365-4362.2002.01681_2.x

[26] Sanli H., Ozdemir E. Ig M class anticardiolipin antibody and anti-Ro/SS-A positivity in urticarial vasculitis associated with hepatitis C virus infection // Int J Dermatol. 2002. Vol. 41, N 12. Р. 930–932. doi: 10.1046/j.1365-4362.2002.01681_2.x

[27] Ito A, Kazama T, Ito K, Ito M. Purpura with cold urticaria in a patient with hepatitis C virus infection-associated mixed cryoglobulinemia type III: Successful treatment with interferon-beta. J Dermatol. 2003;30(4):321–325. doi: 10.1111/j.1346-8138.2003.tb00394.x

[28] Ito A., Kazama T., Ito K., Ito M. Purpura with cold urticaria in a patient with hepatitis C virus infection-associated mixed cryoglobulinemia type III: Successful treatment with interferon-beta // J Dermatol. 2003. Vol. 30, N 4. Р. 321–325. doi: 10.1111/j.1346-8138.2003.tb00394.x

[29] Rego TC, Massumoto CM, Batista RS, et al. The use of monoclonal antibody (rituximab) in the treatment of type II mixed cryoglobulinemia. Braz J Infect Dis. 2007;11(1):174–175. doi: 10.1590/s1413-86702007000100038

[30] Rego T.C., Massumoto C.M., Batista R.S., et al. The use of monoclonal antibody (rituximab) in the treatment of type II mixed cryoglobulinemia // Braz J Infect Dis. 2007. Vol. 11, N 1. Р. 174–175. doi: 10.1590/s1413-86702007000100038

[31] Pinto-Almeida T, Caetano M, Alves R, Selores M. Cutaneous lesions and finger clubbing uncovering hypocomplementemic urticarial vasculitis and hepatitis C with mixed cryoglobulinemia. An Bras Dermatol. 2013;88(6):973–976. doi: 10.1590/abd1806-4841.20132776

[32] Pinto-Almeida T., Caetano M., Alves R., Selores M. Cutaneous lesions and finger clubbing uncovering hypocomplementemic urticarial vasculitis and hepatitis C with mixed cryoglobulinemia // An Bras Dermatol. 2013. Vol. 88, N 6. Р. 973–976. doi: 10.1590/abd1806-4841.20132776

[33] Morgado-Carrasco D, Vargas-Mora P, Fustà-Novell X. Urticarial vasculitis and deep venous thrombosis following administration of intravenous cocaine. Clin Exp Dermatol. 2020;45(5):630–632. doi: 10.1111/ced.14215

[34] Morgado-Carrasco D., Vargas-Mora P., Fustà-Novell X. Urticarial vasculitis and deep venous thrombosis following administration of intravenous cocaine // Clin Exp Dermatol. 2020. Vol. 45, N 5. Р. 630–632. doi: 10.1111/ced.14215

[35] Roccatello D, Saadoun D, Ramos-Casals M, et al. Cryoglobulinaemia. Nat Rev Dis Primers. 2018;4(1):11. doi: 10.1038/s41572-018-0009-4

[36] Roccatello D., Saadoun D., Ramos-Casals M., et al. Cryoglobulinaemia // Nat Rev Dis Primers. 2018. Vol. 4, N 1. Р. 11. doi: 10.1038/s41572-018-0009-4

[37] Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. Clin Exp Rheumatol. 1991;9(6):621–624.

[38] Ferri C., Greco F., Longombardo G., et al. Association between hepatitis C virus and mixed cryoglobulinemia [see comment] // Clin Exp Rheumatol. 1991. Vol. 9, N 6. Р. 621–624.

[39] Ignatova TM, Kozlovskaya LV, Gordovskaya NB, et al. Cryoglobulinemic vasculitis associated with hepatitis C virus: 20 years of treatment experience. Therapeutic Archive. 2017;89(5):46–52. (In Russ). doi: 10.17116/terarkh201789546-52

[40] Игнатова Т.М., Козловская Л.В., Гордовская Н.Б., и др. Криоглобулинемический васкулит, ассоциированный с вирусом гепатита С: 20-летний опыт лечения // Терапевтический архив. 2017. Т. 89, № 5. С. 46–52. doi: 10.17116/terarkh201789546-52

[41] Vasiliev VI, Palshina SG, Logvinenko OA, et al. Cryoglobulinemic vasculitis associated with hepatitis C virus. Therapeutic Archive. 2012;84(5):35–42. (In Russ).

[42] Васильев В.И., Пальшина С.Г., Логвиненко О.А., и др. Криоглобулинемический васкулит, ассоциированный с вирусом гепатита С // Терапевтический архив. 2012. Т. 84, № 5. С. 35–42.

[43] Castillo I, Pardo M, Bartolome J, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis. 2004;189(1):7–14. doi: 10.1086/380202

[44] Castillo I., Pardo M., Bartolome J., et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown // J Infect Dis. 2004. Vol. 189, N 1. Р. 7–14. doi: 10.1086/380202

[45] Milovanova SY. Mixed cryoglobulinemia associated with chronic hepatitis C: Significance in the development of extrahepatic manifestations, treatment methods [dissertation abstract]. Moscow, 2013. 29 р.

[46] Милованова С.Ю. Смешанная криоглобулинемия, ассоциированная с хроническим гепатитом С: значение в развитии внепеченочных проявлений, методы лечения: Автореф. дис. … докт. мед. наук. Москва, 2013. 29 с.

[47] Golovach IY, Yegudina YD. Cryoglobulinemia and cryoglobulinemic vasculitis: Etiological aspects and pathophysiological associations. Modern Rheumatol J. 2020;14(1):78–84. (In Russ). doi: 10.14412/1996-7012-2020-1-78-84

[48] Golovach I.Y., Yegudina Y.D. Cryoglobulinemia and cryoglobulinemic vasculitis: Etiological aspects and pathophysiological associations // Modern Rheumatol J. 2020. Vol. 14, N 1. Р. 78–84. doi: 10.14412/1996-7012-2020-1-78-84

[49] Bouvet JP, Marone G. Protein Fv: An endogenous immunoglobulin superantigen and superallergen. Chem Immunol Allergy. 2007;(93):58–76. doi: 10.1159/000100858

[50] Bouvet J.P., Marone G. Protein Fv: An endogenous immunoglobulin superantigen and superallergen // Chem Immunol Allergy. 2007. N 93. Р. 58–76. doi: 10.1159/000100858

[51] Patella V, Bouvet JP, Marone G. Protein Fv produced during vital hepatitis is a novel activator of human basophils and mast cells. J Immunol. 1993;151(10):5685–5698.

[52] Patella V., Bouvet J.P., Marone G. Protein Fv produced during vital hepatitis is a novel activator of human basophils and mast cells // J Immunol. 1993. Vol. 151, N 10. Р. 5685–5698.

[53] Genovese A, Borgia G, Bouvet JP, et al. Protein Fv produced during viral hepatitis is an endogenous immunoglobulin superantigen activating human heart mast cells. Int Arch Allergy Immunol. 2003;132(4):336–345. doi: 10.1159/000074901

[54] Genovese A., Borgia G., Bouvet J.P., et al. Protein Fv produced during viral hepatitis is an endogenous immunoglobulin superantigen activating human heart mast cells // Int Arch Allergy Immunol. 2003. Vol. 132, N 4. Р. 336–345. doi: 10.1159/000074901

[55] Alberti-Violetti S, Berti E, Marzano AV. Cutaneous and systemic vasculitides in dermatology: A histological perspective. G Ital Dermatol Venereol. 2018;153(2):185–193. doi: 10.23736/S0392-0488.18.05886-8

[56] Alberti-Violetti S., Berti E., Marzano A.V. Cutaneous and systemic vasculitides in dermatology: A histological perspective // G Ital Dermatol Venereol. 2018. Vol. 153, N 2. Р. 185–193. doi: 10.23736/S0392-0488.18.05886-8

[57] Federal clinical guidelines for the treatment of urticaria. Russian Association of Allergists and Immunologists. 2019. (In Russ).

[58] Федеральные клинические рекомендации по лечению крапивницы. Российская Ассоциация аллергологов и иммунологов, 2019.

[59] Puhl V, Bonnekoh H, Scheffel J, et al. A novel histopathological scoring system to distinguish urticarial vasculitis from chronic spontaneous urticaria. Clin Transl Allergy. 2021;11(2):e12031. doi: 10.1002/clt2.12031

[60] Puhl V., Bonnekoh H., Scheffel J., et al. A novel histopathological scoring system to distinguish urticarial vasculitis from chronic spontaneous urticaria // Clin Transl Allergy. 2021. Vol. 11, N 2. Р. e12031. doi: 10.1002/clt2.12031

[61] Danilychev MV, Danilycheva IV, Katunina OV, et al. New technological approaches in the differential diagnosis of chronic spontaneous urticaria and urticarial vasculitis. Physical Fundamentals Instrumentation. 2019;8(4):92–97. (In Russ). doi: 10.25210/jfop-1904-092097

[62] Данилычев М.В., Данилычева И.В., Катунина О.В., и др. Новые технологические подходы в дифференциальной диагностике хронической спонтанной крапивницы и уртикарного васкулита // Физические основы приборостроения. 2019. Т. 8, № 4. C. 92–97. doi: 10.25210/jfop-1904-092097

[63] Dincy CV, George R, Jacob M, et al. Clinicopathologic profile of normocomplementemic and hypocomplementemic urticarial vasculitis: A study from South India. J Eur Acad Dermatol Venereol. 2008;22(7):789–794. doi: 10.1111/j.1468-3083.2007.02641.x

[64] Dincy C.V., George R., Jacob M., et al. Clinicopathologic profile of normocomplementemic and hypocomplementemic urticarial vasculitis: A study from South India // J Eur Acad Dermatol Venereol. 2008. Vol. 22, N 7. Р. 789–794. doi: 10.1111/j.1468-3083.2007.02641.x

[65] Borzova EY. Biomarkers of local and systemic inflammation in chronic urticaria [dissertation abstract]. Moscow; 2013. 42 р. (In Russ).

[66] Борзова Е.Ю. Биомаркеры локального и системного воспаления при хронической крапивнице: Автореф. дис. … докт. мед. наук. Москва, 2013. 42 с.

[67] Shirokova EN, Ivashkin VT. Modern therapy of chronic viral hepatitis C. Russ Medicine. 2002;10(16):694–696. (In Russ).

[68] Широкова Е.Н., Ивашкин В.Т. Современная терапия хронического вирусного гепатита С // Русская медицина. 2002. Т. 10, № 16. C. 694–696.

[69] World Health Organization [Internet]. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection [cites 1 July 2018]. Available from: https://www.who.int/publications/i/item/9789241550345. Accessed: 15.12.2022.

[70] World Health Organization [интернет]. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection [cites 1 July 2018]. Режим доступа: https://www.who.int/publications/i/item/9789241550345. Дата обращения: 15.12.2022.

[71] Chronic viral hepatitis C. Clinical recommendations (Approved by the Ministry of Health of the Russian Federation). 2021. (In Russ).

[72] Хронический вирусный гепатит С. Клинические рекомендации (Утверждены Минздравом РФ). 2021.

[73] Cacoub P, Terrier B, Saadoun D. Hepatitis C virus-induced vasculitis: Therapeutic options. Ann Rheum Dis. 2014;73(1):24–30. doi: 10.1136/annrheumdis-2013-203883

[74] Cacoub P., Terrier B., Saadoun D. Hepatitis C virus-induced vasculitis: therapeutic options // Ann Rheum Dis. 2014. Vol. 73, N 1. Р. 24–30. doi: 10.1136/annrheumdis-2013-203883

[75] Kolkhir P, Bonnekoh H, Kocatürk E, et al. Management of urticarial vasculitis: A worldwide physician perspective. World Allergy Organ J. 2020;13(3):100107. doi: 10.1016/j.waojou.2020.100107

[76] Kolkhir P., Bonnekoh H., Kocatürk E., еt al. Management of urticarial vasculitis: A worldwide physician perspective // World Allergy Organ J. 2020. Vol. 13, N 3. Р. 100107. doi: 10.1016/j.waojou.2020.100107

[77] Nucera E, Basta F, Buonomo A, et al. A case of hypocomplementemic urticarial vasculitis syndrome successfully treated with omalizumab. J Investig Allergol Clin Immunol. 2017;27(6):382–384. doi: 10.18176/jiaci.0191

[78] Nucera E., Basta F., Buonomo A., et al. A case of hypocomplementemic urticarial vasculitis syndrome successfully treated with omalizumab // J Investig Allergol Clin Immunol. 2017. Vol. 27, N 6. Р. 382–384. doi: 10.18176/jiaci.0191

[79] Del Pozo ME, Saenz NP, Vera JG, Tiro JL. Vasculitic urticaria treated with omalizumab. Case Report. World Allergy Organ J. 2012;5(Suppl 2):S106. doi: 10.1097/01.WOX.0000412031.62254.da

[80] Del Pozo M.E., Saenz N.P., Vera J.G., Tiro J.L. Vasculitic urticaria treated with omalizumab // Case Report World Allergy Organ J. 2012. Vol. 5, Suppl 2. Р. S106. doi: 10.1097/01.WOX.0000412031.62254.da

[81] Bettuzzi T, Deroux A, Jachiet M, et al Dramatic but suspensive effect of interleukin-1 inhibitors for persistent urticarial vasculitis: A French multicentre retrospective study. Ann Rheum Dis. 2019;78(10):1446–1448. doi: 10.1136/annrheumdis-2019-215605

[82] Bettuzzi T., Deroux A., Jachiet M., et al. Dramatic but suspensive effect of interleukin-1 inhibitors for persistent urticarial vasculitis: A French multicentre retrospective study // Ann Rheum Dis. 2019. Vol. 78, N 10. Р. 1446–1448. doi: 10.1136/annrheumdis-2019-215605

[83] Krause K, Mahamed A, Weller K, et al. Efficacy and safety of canakinumab in urticarial vasculitis: An open-label study. J Allergy Clin Immunol. 2013;132(3):751–754.e5. doi: 10.1016/j.jaci.2013.04.008

[84] Krause K., Mahamed A., Weller K., et al. Efficacy and safety of canakinumab in urticarial vasculitis: An open-label study // J Allergy Clin Immunol. 2013. Vol. 132, N 3. Р. 751–754.e5. doi: 10.1016/j.jaci.2013.04.008

[85] Leiva-Salinas M, Francés L, Marin-Cabanas I, et al. Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C. J Eur Acad Dermatol Venereol. 2015;29(5):1027–1028. doi: 10.1111/jdv.12450

[86] Leiva-Salinas M., Francés L., Marin-Cabanas I., et al. Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C // J Eur Acad Dermatol Venereol. 2015. Vol. 29, N 5. Р. 1027–1028. doi: 10.1111/jdv.12450

[87] Suárez F, Pulpillo-Ruiz Á, Zulueta Dorado T, Conejo-Mir Sánchez J. Urticarial vasculitis: A retrospective study of 15 cases. Actas Dermosifiliogr. 2013;104(7):579–585. doi: 10.1016/j.adengl.2012.12.005

[88] Suárez F., Pulpillo-Ruiz Á., Zulueta Dorado T., Conejo-Mir Sánchez J. Urticarial vasculitis: A retrospective study of 15 cases // Actas Dermosifiliogr. 2013. Vol. 104, N 7. Р. 579–585. doi: 10.1016/j.adengl.2012.12.005

[89] Sanchez NP, Winkelmann RK, Schroeter AL, Dicken CH. The clinical and histopathologic spectrums of urticarial vasculitis: Study of forty cases. J Am Acad Dermatol. 1982;7(5):599–605. doi: 10.1016/s0190-9622(82)70139-2

[90] Sanchez N.P., Winkelmann R.K., Schroeter A.L., Dicken C.H. The clinical and histopathologic spectrums of urticarial vasculitis: Study of forty cases // J Am Acad Dermatol. 1982. Vol. 7, N 5. Р. 599–605. doi: 10.1016/s0190-9622(82)70139-2

[91] Callen JP, Kalbfleisch S. Urticarial vasculitis: A report of nine cases and review of the literature. Br J Dermatol. 1982;107(1):87–93. doi: 10.1111/j.1365-2133.1982.tb00295.x

[92] Callen J.P., Kalbfleisch S. Urticarial vasculitis: A report of nine cases and review of the literature // Br J Dermatol. 1982. Vol. 107, N 1. Р. 87–93. doi: 10.1111/j.1365-2133.1982.tb00295.x

[93] Fang PP, Lindner M, Steinberg JS, et al. [Klinische Anwendungen der OCT-Angiographie]. Ophthalmologe. 2016;113(1):14–22. (In German). doi: 10.1007/s00347-015-0192-6

[94] Fang P.P., Lindner M., Steinberg J.S., et al. [Klinische Anwendungen der OCT-Angiographie] // Ophthalmologe. 2016. Vol. 113, N 1. Р. 14–22. German. doi: 10.1007/s00347-015-0192-6

RIGHTS & PERMISSIONS

Teplyakova K.S.